Want to see FR:ALMIB full AI Analyst Report?
ALMIB Stock Chart & Stats
€1.08
-€0.01(-1.20%)
At close: 4:00 PM EST
€1.08
-€0.01(-1.20%)
Day’s Range― - ―
52-Week Range€0.73 - €1.20
Previous CloseN/A
Volume10.38K
Average Volume (3M)268.33K
Market Cap
€59.12M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio1.14
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary Biological IPOwning a unique microorganism strain creates a structural competitive advantage: it provides a differentiated product platform, supports IP protection and exclusivity, and enables licensing or partner exclusives that can sustain revenue streams once regulatory approvals and commercial scale are achieved.
Multi-market Addressable ModelServing both agricultural biocontrol and industrial/water remediation diversifies end markets and reduces dependence on a single sales channel. This cross-market applicability increases long-term commercial opportunity and resilience if one sector faces regulatory or demand headwinds.
Flexible Revenue Routes (sales, Distribution, Licensing)A business model that permits direct sales, partner distribution, and licensing creates scalable commercialization paths. Partners can accelerate market access and reduce capex needs, while licensing can deliver recurring royalties—durable options to monetize the proprietary strain over time.
Bears Say
Revenue Collapse And Inconsistent SalesA collapse to effectively zero revenue in 2025 signals a severe commercialization or market-access failure. Without stable, recurring sales it's difficult to achieve scale economies or fund commercialization, making future margin recovery and investment self-funding materially uncertain.
Negative Equity And Rising LeverageSustained negative equity combined with materially higher debt reduces financial flexibility and raises refinancing risk. This capital structure weakens the company's ability to absorb setbacks, increases financing costs or dilution risk, and constrains investment in commercialization or R&D.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates ongoing cash burn and reliance on external funding. Over months this undermines the firm’s ability to fund approvals, scale manufacturing, or support partners without dilution or debt, threatening long-term viability absent revenue pickup.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.73 and its highest was €1.20 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €59.12M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 80 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.112%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in FR:ALMIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.
Technical Analysis
Options Prices
Currently, No data available
---